+

WO1994017841A1 - Greffes biologiques ayant des differences par region sur le plan de la densite de reticulation et methodes de fabrication - Google Patents

Greffes biologiques ayant des differences par region sur le plan de la densite de reticulation et methodes de fabrication Download PDF

Info

Publication number
WO1994017841A1
WO1994017841A1 PCT/US1994/001012 US9401012W WO9417841A1 WO 1994017841 A1 WO1994017841 A1 WO 1994017841A1 US 9401012 W US9401012 W US 9401012W WO 9417841 A1 WO9417841 A1 WO 9417841A1
Authority
WO
WIPO (PCT)
Prior art keywords
cross
graft
linking agent
cross linking
link density
Prior art date
Application number
PCT/US1994/001012
Other languages
English (en)
Inventor
Roger Tu
Edwin Wang
Original Assignee
Baxter International Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter International Inc. filed Critical Baxter International Inc.
Publication of WO1994017841A1 publication Critical patent/WO1994017841A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Definitions

  • the present invention relates generally to biological grafts, such as vascular prostheses, skin grafts, heart valves and the like. More particularly, the present invention relates to the preparation of collagenous graft materials having regionalized differences in cross link density to promote improved biocompatibility following implantation.
  • tissue of biological origin have been used for allogenic and xenogeneic grafting in human beings.
  • certain cardiovascular tissues e.g., segments of blood vessels, heart valves
  • integumentary tissues e.g., skin grafts
  • Tissue useable for allogenic or xenogeneic grafting may contain substantial amounts of connective tissue.
  • Such connective tissue forms a supportive framework within which the functional cellular structure of the tissue is disposed.
  • the flexibility or rigidity of the connective tissue framework depends largely on the proportions of collagen and elastin contained within such tissue and/or the structure and configuration of the collagen/elastin fiber network thereof.
  • Naturally occurring collagen molecules typically consist of three polypeptide chains intertwined in a coiled helical confirmation. The individual amino acid constituents of each polypeptide chain are connected, by way of carbon bonds, to adjacent a ino acids of a neighboring polypeptide chain. Such amino acid bonding holds the polypeptide chains in the triple helical confirmation of the collagen molecule.
  • Collagenous biological tissues may be termed or pressured for subsequent surgical grafting and/or implantation through a "fixing" process whereby the collagen network is exposed to one or more chemical compounds capable of cross linking the collagen molecules to one another. Both intramolecular and intermolecular collagen cross linkages may be formed when the collagenous tissue is exposed to such collagen cross linking chemical fixative.
  • collagen cross linking fixatives include formaldehyde, glutaraldehyde, dialdehyde starch, hexamethylene diisocyanate and certain polyepoxy compounds including glycol diglycidyl ether, polyol polyglycydyl ether and dicarboxylic acid diglycidyl ester.
  • formaldehyde glutaraldehyde
  • dialdehyde starch hexamethylene diisocyanate
  • certain polyepoxy compounds including glycol diglycidyl ether, polyol polyglycydyl ether and dicarboxylic acid diglycidyl ester.
  • Three (3) specific water soluble polyepoxy compounds which may be used as collagen cross linking agents are shown below:
  • the low molecular weight fixatives such as glutaraldehyde or formaldehyde
  • the high molecular weight fixatives such as the polyepoxy compounds
  • the cross link density or number of cross linkages formed may be a function of the exposure time to the particular fixative.
  • the cross link density may be effected by other factors including a) the concentration of the fixative solution, b) the pH of the fixative solution, and c) physical conditions such as temperature and pressure.
  • the cross link density is generally correlated to the denaturation temperature of a cross linked collagenous material. In other words, a cross linked material with a higher denaturation temperature has a higher cross link density.
  • a fresh collagenous material has its baseline denaturation temperature (T 0 ) .
  • T f final denaturation temperature
  • T f final denaturation temperature
  • a fresh bovine artery has its baseline denaturation temperature of 65°C.
  • the cross linked artery has a denaturation temperature of 80°C.
  • the maximum denaturation temperature of a bovine artery is about 85°C. Therefore, the cross link density is calculated as
  • the residual chemical cross linking agent contained within the graft may adversely affect the biocompatibility and/or tissue affinity of the graft material.
  • Prior investigators have attempted to deal with the problem of decreased biocompatibility by neutralizing or deactivating any residual or unreacted cross linking agent within the graft through exposure of the graft to a second chemical solution capable of deactivating or neutralizing same residual unreacted fixative (e.g., free aldehyde groups) within the biograft material.
  • Examples of prior United States patents which describe methods whereby collagenous graft materials are treated with fixative deactivating or neutralizing chemical agents include U.S. Patent No. 3,974,526 (Dardik) entitled VASCULAR PROSTHESES AND PROCESS FOR PRODUCING THE SAME; U.S. Patent No. 3,988,782 (Dardik) entitled NON-ANTIGENIC, NON-THROMBOGENIC INFECTION-RESISTANT GRAFTS FROM UMBILICAL CORD VESSELS AND PROCESSES FOR PREPARING AND USING SAME and U.S. Patent No. 4,553,974 (Dewanjee) entitled TREATMENT OF COLLAGENOUS TISSUE WITH GLUTARALDEHYDE AND AMINODIPHOSPHONATE CALCIFICATION INHIBITOR.
  • fixative deactivating or neutralizing chemical agents e.g., amino acids
  • fixative chemical present in a particular region, portion or surface of a graft may affect the bio-affinity of that portion or surface of the graft.
  • sufficient bio-affinity is required to enable the tissue graft to undergo endothelialization either via blood stream regeneration or via in vitro endothelialization in a lab.
  • vascular grafts of biological origin are typically implanted to a host blood vessel by way of end- to-end anastomosis of such that blood will flow directly through the lumen of the graft.
  • the ends of the vascular graft are typically in abutting contact with the adjacent ends of the host blood vessel.
  • the luminal surface of the graft is in intimate contact with the circulating blood of the host.
  • the ends and luminal surface of such graft must have sufficient bio- affinity to undergo and maintain such direct host contact.
  • the adventitial surface of the vascular graft is, however, subject to a lesser degree of contact with the host tissue and, accordingly, may be able to tolerate a higher degree of residual fixative or higher cross link density than those portions if the graft which maintain direct or intimate contact with the neighboring host tissues.
  • a skin graft e.g., permanent or temporary patch graft
  • the periphery of a skin graft may be sutured directly to or positioned adjacent the neighboring integumentary tissue and, as a result, graft-host reactions are most likely to occur at the suture line or interface between the graft tissue and the neighboring host integument.
  • the underside of the skin graft typically rests against subcutaneous adipose tissue which is comparatively unlikely to evoke an adverse graft-host reaction.
  • the underside (i.e., body contacting surface) of the graft may be likely to evoke a graft-host reaction, or to impede healing of injured tissues underlying the graft.
  • the outer surface of the graft i.e., non- body contacting surface
  • the present invention provides biological grafts formed of chemically cross linked collagenous material, wherein each graft comprises a) a first region wherein said collagen is cross linked to a first cross link density; and b) a second region wherein said collagen is cross linked to a second cross-link density different from said first cross link density.
  • the biological grafts of the present invention may be of any suitable mammalian origin (e.g. , bovine, porcine, canine, human, etc.
  • tubular grafts e.g., blood vessel, ureter, etc.
  • flat or short-like grafts e.g., skin grafts, pericardium
  • functional anatomical structures e.g., heart valves, venous valves, etc.
  • a first region of each graft is exposed to a first fixative agent under a first set of conditions (e.g., pH, temperature, pressure, exposure, time) to cause said first region to be cross linked to said first cross link density and wherein said second region is exposed to a second set of conditions to cause said second region to be cross linked to said second cross link density different from said first cross link density.
  • a first set of conditions e.g., pH, temperature, pressure, exposure, time
  • Figure 1 is a schematic diagram of a basic apparatus of the present invention whereby a segment of tubular graft material is prepared for surgical implantation.
  • Figure 2a is a schematic showing of an alternative embodiment of an apparatus of the present invention.
  • Figure 2b is an enlarged perspective view of one solution feeder manifold component of the apparatus shown in Figure 2a.
  • Figure 2c is an enlarged view of portion 2c of Figure 2a.
  • Figure 3a is a schematic showing of an alternative embodiment of an apparatus of the invention whereby a flat segment of biological graft material (eg. , a skin graft) is prepared for subsequent surgical implantation.
  • Figure 3b is an exploded view of the bulkhead assembly portion of the apparatus shown in Figure 3a.
  • Figure 3c is a cross-sectional view through line 3c- 3c of Figure 3a.
  • Figure 4a is a schematic showing of an alternative embodiment of an apparatus of the present invention whereby a segment of tubular graft material (e.g., a blood vessel) is prepared for surgical implantation.
  • a segment of tubular graft material e.g., a blood vessel
  • Figure 4b is an enlarged cross-sectional view of portion 4b of Figure 4a.
  • Figure 4c is an enlarged perspective view of one graft mounting fixture of the apparatus shown in Figure 4a.
  • FIG 1 is a schematic showing of a basic apparatus 10 of the present invention.
  • the apparatus 10 of Figure 1 is a schematic showing of a basic apparatus 10 of the present invention.
  • tubular graft materials e.g. , blood vessel segments, segments of ureter, etc. .
  • the apparatus 10 shown in Figure 1 comprises a bath chamber 12 wherein a quantity of a first fixative solution 14 is contained.
  • the apparatus 10 further comprises a reservoir 16 wherein a quantity of a second fixative solution 18 is contained.
  • a second fixative solution feed line 22 is inserted through an outlet port 24 near the bottom of reservoir 16.
  • Feed line 22 extends through endwall 26 of bath 12.
  • a fluid tight seal is formed by endwall 26, about the outer surface of inflow tube 22, so as to prevent leakage around the inflow tube 22 at its point of insertion through endwall 26 and into reservoir 12.
  • a pump P such as a peristaltic pump, is positioned on feed line 22 to pump a flow of second fixative solution 18 from reservoir 16, through feed line 22.
  • a return line 28 extends outwardly through endwall 30 of reservoir 12. Endwall 30 of reservoir 12 forms a fluid tight seal about the outer surface of return line 28 so as to avoid leakage around return line 28 at its point of emergence from reservoir 12.
  • the opposite end of return line 28 is fluidly connected to inlet port 30 formed in the top of reservoir 16.
  • a segment of tubular graft material 32 (e.g., a cut section of blood vessel) is submersed within the first fixative solution 14 contained within reservoir 12.
  • the inflow end IE of tubular graft 32 is passed over the adjacent end of feed line 22 and secured thereon by way of ligature 34.
  • the outflow end OE of tubular graft 32 is passed over the adjacent end of return line 28 and secured thereon by ligature 36.
  • pump P may be operated through to continually or intermittently pump a flow of second fixative solution 18 through the lumen 40 of tubular graft 32, while the adventitial surface of graft 32 remains directly exposed to the first fixative solution 14 contained within bath 12.
  • the first fixative solution 14 within bath 12 will be of a higher concentration, higher reactivity, or otherwise maintained under conditions (e.g., exposure time, pH, temperature, pressure) capable of effecting a higher cross link density within the tissue of graft 32, than is the second solution 18 which passes through the lumen 40 of the graft 32.
  • the adventitial surface of graft 32 will be coming in contact with first fixative solution 14 and will have a higher collagen cross link density than will the luminal surface of graft 32 coming in contact with second fixative solution 18.
  • the lower collagen cross link density of the luminal surface of the graft 32 will result in improved bio-compatibility or bio-affinity between the graft 32 and the blood subsequently circulated therethrough.
  • the higher cross link density of the outer or adventitial portion of graft ' 32 will result in adequate fixation and preservation of the graft tissue so as to ensure that the graft 32 as a whole has been adequately preserved and will exhibit adequately shelf stability.
  • first and second fixative solutions of varying concentration may be utilized to bring about the desired regionalized variations in cross link density of the graft 32
  • various other conditions such as temperature and pressure, may also be varied for purposes of controlling the relative cross link densities of regionalized portions of the graft, irrespective of whether the fixative solution(s) exposed thereto differ in concentration or chemical content.
  • an apparatus 10a of the present invention incorporating flow-enhancing and temperature control elements to provide for controlled regionalized variations in cross link density of the graft material 32b.
  • a heater 60 is operatively mounted on or connected to reservoir 12a so as to warm the first fixative solution 14a contained within reservoir 12a.
  • Such heater 60 may comprise an immersion type heater or positioned within the reservoir 12a or may comprise an externally mounted heater positioned outside the reservoir and fluidly connected thereto such that the first fixative solution 14a may be circulated therethrough.
  • a pu p may be incorporated within or utilized in connection with the heater 60 so as to pump the first fixative solution 14a through heater 60.
  • Heater 60 is preferably provided with a thermostat mechanism operative to provide continuous control of the temperature of the first fixative solution 14a within bath 12a.
  • the reservoir 16a wherein the second fixative solution 18a is contained may be positioned on a height-adjustable jack stand 62 such that the height of the fluid level within reservoir 16a may be adjusted relative to the heights of other components of the apparatus 10a.
  • first and second vestibular chambers 64, 66 are positioned adjacent opposite endwalls 26a, 30a of bath 12a. The first vestibular chamber 64 is positioned at a higher level than the second vesitbular chamber 66 so as to cause gravity enhanced continuity of flow through the lumen of graft 32a.
  • a primary feed tube 22a fluidly connects the outlet port 24a of reservoir 16a to the interior of first vestibular chamber 64.
  • a secondary feed tube 68 extends from the interior of first vestibular chamber 64, through endwall 26a and into the interior of bath 12a.
  • a primary return tube 28 fluidly connects the second vestibular chamber 66 to the inlet 30a of reservoir 16a, while a secondary return line 70 extends from the interior of second vestibular chamber 66, through endwall 30a and into the interior of bath 12a.
  • the inlet and i.e., of graft 32a is affixed, by ligature, 34a, to the adjacent end of secondary feed tube 68, while the outflow end OE of graft 32a is affixed by ligature 36a to the adjacent end of secondary outflow tube 70.
  • Figure 2c is an enlarged view of a preferred connector whereby one of the ends of the graft 32, 32a may be operatively connected to the adjacent primary or secondary feed 22, 28 or return 68, 70 tubing.
  • the outflow end OE of a tubular graft 32a is passed over a male Leur connector 72 and secured thereon by way of ligature 36a.
  • Secondary return tube 70 is fluidly connected to a female Leur connector 74.
  • the male Leur connector 72 may, thus, be easily connected to/disconnected from the female Leur connector 74, thereby facilitating placement and removal of the graft 32a within the apparatus 10a.
  • any apparatus of the present invention may be designed to simultaneously treat a plurality or multiplicity of grafts, rather than one single graft as shown in Figures l, 2a or 3a.
  • Figure 2b shows a modified vestibular chamber 64 designed for use with six(6) separate tubular grafts by way of six(6) separate secondary feed tubes 68a-f extending therefrom.
  • the opposite end vestibular chamber 66 may also be equipped with six(6) separate secondary outflow tubes arranged directly across from, and in alignment with the six(6) secondary feeder tubes 68a-f of vestibular chamber 66, so as to permit simultaneous mounting and treatment of six (6) tubular graft segments 32, 32a within the bath chamber 12a.
  • the size and configuration of the apparatus may be further modified to simultaneously treat fewer or more separate graft segments, as desired.
  • FIGS 3a-3c show an alternative embodiment of an apparatus of the present invention designed for treatment of flat segments of graft material such as segments of pericardium or skin.
  • This apparatus comprises a container or bath chamber 80 having a bulkhead/graft mounting assembly 82 mounted therein.
  • the bath chamber 80 is formed in a generally rectangular box-like configuration, but may alternatively be configured in any other shapes or configurations capable of performing the function of the bath chamber 80.
  • Bulkhead/graft mounting fixture 82 is shown in exploded view in Figure 3b.
  • the bulkhead/graft mounting fixture 82 comprises a first bulkhead member 84 and a second bulkhead member 86.
  • the first and second bulkhead members 84, 86 each have at least one aperture 88, 90 formed therein, said apertures 88, 90 being directly alignable, as shown.
  • 0-ring mounting grooves 92 (not shown) are formed on the inboard surfaces of the first and second bulkhead members 84, 86 around each aperture 88, 90.
  • Directly alignable fastener receiving apertures 98 are formed in each first and second bulkhead member 84, 86 to permit passage therethrough of fastening members 100, such as screws or bolts to hold the first and second bulkhead members 84, 86 in close-spaced juxtaposition to one another as shown in Figure 3c.
  • the first and second bulkhead members 84 86 When so positioned, the first and second bulkhead members 84 86 will exert inward pressure on washers or 0-rings 94, 96, thereby compressing and holding the segment of flat graft material 102 in an operative position between apertures 88 and 90.
  • the fully assembled bulkhead/graft mounting fixture 82 is then inserted downwardly such that the lateral ends of the bulkhead/graft mounting fixture 82 are slideably received within opposing placement grooves or tracks 104, 106 formed in the inboard surfaces of the sidewalls of bath chamber 80.
  • a similar groove or other sealing member may be formed on the floor of the bath chamber 80 such that, when fully inserted, the bottom edge of the bulkhead/graft mounting fixture 82 will seal against the floor of the bath chamber 80.
  • the operatively positioned bulkhead/graft mounting fixture 82 forms a fluid tight seal in combination with the sidewalls and floor of the bath chamber, thereby dividing the bath chamber into a first fluid chamber 108 and a second fluid chamber 110.
  • First fixative solution 14b is placed in the first fluid chamber 108 and a second fixative solution 18b is placed in the second fluid chamber 110.
  • the one side of the graft 102 is exposed to the first fixative solution 14b while the opposite side of the graft 102 is exposed to the second fixative solution 18b.
  • cross-link densities of the right and left sides of the graft 102 may be varied independently of one another.
  • a flat segment of graft material 102 having a first cross-link density on one side thereof, and a second cross link density on the other side thereof.
  • the present invention may also be employed to produce elongate or tubular grafts 202 having different cross-link densities at their ends, than in the mid- regions thereof.
  • Figures 4a-c show an alternative embodiment 200 of the present invention operative to prepare a segment of tubular graft material 202 such that the mid-region MR of the graft 202 is exposed to a first fixative solution 14c, while at least the adventitial and luminal surfaces of the lateral ends LE of the graft segment 202 are exposed to a second fixative solution 18c.
  • the cross link densities of the lateral ends LE of the graft 202 may be higher, lower or independently different from the cross link density of the mid-region MR of the graft 202.
  • the apparatus 200 shown in Figures 4a-4c comprises a main bath chamber 204 having first 106 and second 108 segmented bulkheads positioned therein, as shown, to divide the main bath chamber 204 into a middle bath chamber 208 and right and left lateral end chambers 210R and 210L.
  • the segmented bulkheads 106, 108 form fluid tight seals about the adventitial surface of graft 202 to prevent leakage from the middle bath chamber 208 into the lateral end bath chambers 210R or 210L and vice versa.
  • a feed tube 214 fluidly connects outlet port 216 of reservoir 212 to the inflow end i.e., of the lumen of graft 202.
  • a return tube 218 fluidly connects the outflow end OE of the lumen of graft 202 to the return inlet port 220 of reservoir 212.
  • Pump P may thus be operated to continually or intermittently pump a flow of first fixative solution 14c from reservoir 212, through the lumen of at least the mid-region MR of graft 202.
  • the adventitial (outer) and luminal (inner) surfaces of the mid-region MR of graft 202 are simultaneously exposed to the first fixative solution 14c contained in the middle bath chamber 208 and circulating from reservoir 14c.
  • the lateral end portions of IE and OE of the graft are exposed to the second fixative solution 18c contained in the lateral end bath chambers 210R and 210L.
  • the concentration, chemical content, exposure time and/or conditions of second fixative solution 18c may differ from that of the first solution 14c, so as to result in a lower cross link density at the lateral ends IE, OE, than that which results from exposure of the mid-region MR of the graft 202 to the first fixative solution 14c.
  • the second fixative solution 18c may be desirable to permit the second fixative solution 18c to directly contact the luminal (inner) surfaces of the graft lying outboard of the bulkheads 106 and 108. If the ends of the graft 200 fit snugly over the outer surface of feed tube 214 and return tube 216, such may prevent the second fixative solution 18c from so contacting the luminal (inner) surfaces of the ends of the graft 202.
  • Figures 4b and 4c show means by which the lateral ends OE and IE of the graft 202 may be pulled away from the outer surfaces of feed tube 214 and return tube 216 so as to permit the second fixative solution 18c to contact not only the adventitial (outer) surface and cut end of the graft, but also that portion of the luminal (inner) surface of the graft which lies outboard of the bulkheads 106, 108.
  • the ends of the feed tube 214 and return tube 216 may be provided with raised lifting members 220 such as beads or ridges formed on the outer surface of tubes 214 and 216.
  • lifting members 220 will be sized, configured and positioned to hold the lateral ends OE and IE of graft 202 a spaced distance apart from the outer surface of tubes 214 and 216 so as to allow the second fixative solution 18c contained within lateral end chambers 210R 210L to contact those portions of the luminal surface of the graft 202 which extends outboard of bulkheads 106, 108.
  • an enlarged rim 222 may be formed about the ends of feed tube 214 and/or return tube 216 with a corresponding depression or groove 224 being formed in bulkheads 106, 108.
  • Receiving groove 224 is sized relative to the raised rim 222 such that, when the end of tube 214 or 216 is seated within the raised groove 224 of bulkhead 106 or 108, the wall of graft 202 will be tightly compressed or held between rim 222 and the surrounding annular groove 224, so as to thereby form a fluid tight seal therebetween.
  • pump P is energized to pump first fixative solution 14c through the lumen of graft 202.
  • the luminal and adventitial surfaces of the mid-region MR of graft 202 are thereby simultaneously treated with the first fixative solution 14c, while the lateral ends OE and IE of graft 202 are treated with the second fixative solution 18c.
  • the first fixative solution may contain a second active ingredient such as aspirin, heparin or antibiotic agent so as to cause the tissue surface of reduced cross link density having an additional therapeutical capability.
  • a second active ingredient such as aspirin, heparin or antibiotic agent
  • a segment of mammalian blood vessel (e.g., bovine coronary artery) is removed from a donor animal and cut to a desired length.
  • the segment of blood vessel is thoroughly cleaned with sterile saline solution and excess surrounding connective tissue is trimmed away. Any unwanted branches of the artery are ligated through the use of standard surgical technique and surgical suture materials.
  • the outflow end OE of the blood vessel graft 32a is advanced over the end of secondary outflow tube 70 and a ligature 36a is applied to firmly hold the outflow end OE of graft 32a thereon.
  • the inflow end IE of graft 32a is advanced over the adjacent end of secondary feed tube 68 and ligature 34a is applied to hold the inflow end IE of graft 32a on the secondary feed tube 68.
  • the first fixative solution 14a consists of a 4% aqueous solution of DenacolTM EX-313 glycerol polyglycidyl ether (Nagase Chemicals, Ltd.). Such 4% DenacolTM EX-313 solution is placed in bath 12a and heating apparatus 60 is set to maintain a bath temperature of approximately 37° C. The level of the 4% DenacolTM EX-313 solution within bath 12a is maintained at sufficient height to ensure that the entire adventitial surface of the graft 32a remains submersed in or covered by the 4% DenacolTM EX-313 solution.
  • the second fixative solution 18a consists of an 0.5% aqueous solution of DenacolTM EX-313.
  • Such 0.5% DenacolTM EX-313 solution is placed in reservoir 16a and vestibular chambers 64 and 66.
  • Pump P is operated to maintain a continuous flow of the 0.5% DenacolTM EX-313 solution through the lumen of graft 32a.
  • the temperature of the 0.5% DenacolTM EX-313 solution is monitored by temperature indicator 31 and, in this example, is maintained at approximately room temperature.
  • the 0.5% DenacolTM EX-313 solution may be removed and replaced with 0.9% saline or other relatively inert liquid so as to halt the cross linking reaction.
  • the saline solution or other inert liquid is then circulated through the lumen of graft 32a by pump P for the remainder of the treatment.
  • Such inert liquid further serves to keep the luminal surface of the graft well hydrated, without promoting further cross linking thereof.
  • This inert liquid may contain anti-thrombotic agent (e.g., heparin) , anti-coagulation agent (e.g., aspirin) or anti-biotic agent to deposit said therapeutic agent onto the graft lumen. Pressure may be applied to enhance the deposition efficiency.
  • anti-thrombotic agent e.g., heparin
  • anti-coagulation agent e.g., aspirin
  • anti-biotic agent e.g., aspirin
  • ligatures 34a and 36a are removed and the graft 32a is extracted from the apparatus 10a.
  • the fixed graft 32a is then washed and cut to its desired length and stored in a suitable medium (e.g., ethanol) for subsequent surgical implantation.
  • a suitable medium e.g., ethanol
  • a generally rectangular patch of mammalian skin e.g., porcine skin
  • the graft 102 is then washed and cleaned in accordance with standard pre-fixation techniques.
  • O-rings 94-96 are positioned with 0-ring receiving groups 92 and (not shown) on the inner surfaces of 84 and 86.
  • the graft 102 is positioned between O-rings 94 and 96 and screws 100 are passed through apertures 98 so as to securely fasten the right and left members 84-86 of bulkhead/graft mounting fixture 82 in juxtaposition, with pressure being exerted by O-rings 94-96 against the outer surfaces of graft 102. Thereafter, the bulkhead/graft mounting fixture 82 is inserted downwardly in receiving tracks 104 of chamber 80.
  • a first solution 14b consisting of 0.5% DenacolTM is based in the left chamber 108 of bath 80 while a second fixation solution 110 consisting of 0.5% aqueous glutaraldehyde is placed in the right chamber 110 of bath 80.
  • the right-side surface of graft 102 becomes substantially fully cross linked (i.e., cross link density of 80-90%) in less than five seconds.
  • the 0.5% DenacolTM solution contained in the left chamber 108 of bath 80 is, on the other hand, a slow acting fixative. Accordingly, the cross link density of the left side of graft 102 may be controlled by the exposure time of the left-side surface of graft 102 to the 0.5% DenacolTM EX-313 solution contained in the left chamber 108.
  • the exposure time of the 0.5% DenacolTM EX-313 to the left-side surface of graft 102 may be varied to effect a desired degree of cross link density of graft 102. With this particular fixative, a 20-30% cross link density is typically believed to be non-antigenic and desirable. At room temperature, such 30% cross link density of the left- side of graft 102 may be achieved by exposure to the 0.5% DenacolTM EX-313 for a period of approximately 5- 10 hours.
  • the bulkhead/graft mounting fixture 82 is removed from the apparatus 200.
  • the bulkhead/graft mounting fixture 82 is then disassembled and the graft 102 is removed.
  • Graft 102 is then washed, cut its desired size and shape, and stored in a suitable storage solution (e.g., ethanol) until surgical implantation.
  • a suitable storage solution e.g., ethanol
  • a segment of mammalian blood vessel (e.g., bovine coronary artery) is removed from a donor animal and cut to a desired length.
  • the segment of blood vessel is thoroughly cleaned with sterile saline solution and excess surrounding connective tissue is trimmed away. Any unwanted branches of the artery are ligated through the use of standard surgical technique and surgical suture materials.
  • the outflow end OE of the blood vessel graft 32a is advanced over the end of the secondary outflow tube 70 and a ligature 36a is applied to from the outflow end OE of the graft 32a thereon.
  • the inflow end IE of graft 32a is advanced over the adjacent end of secondary feed tube 68 and ligature 34a is applied to hold the inflow and IE of graft 32a on the secondary feed tube 68.
  • the first 14a and second 18a fixative solutions consist of the same 4% aqueous solution of DenacolTM Ex-313 glycerol polyglycidyl ether (Nagase Chemicals, Ltd.).
  • the second fixative solution 18a to which the luminal surface of the graft 32a is subjected is maintained at a temperature less than that of the first solution to which the adventitial surface is subjected.
  • the temperature of the second fixative solution 18a to which the luminal surface of the graft 32a is subjected may be 20-50° C and preferably 25- 40°C.
  • a single fixative solution is used under different temperatures to effect different cross link densities on the adventitial and luminal surfaces of a vascular graft.
  • segments of bovine coronary artery are prepared and mounted in the device shown in Figure 2a in the manner described in Example 3 hereabove.
  • the first fixative solution 14a to which the adventitial surface of the graft 32a is subjected consists of 4% DenacolTM Ex-313 glycerol polyglycidyl ether (Nagase Chemicals, Ltd.) while the second fixative solution 18a to which the luminal surface of the graft 32a is subjected consists of 1% DenacolTM Ex- 313 glycerol polyglycidyl ether solution.
  • both the first 14a(4% DenacolTM Ex- 313) and second 18a(1% DenacolTM Ex-313) solutions are maintained at 37° C, and the exposure times for each solution are varied to effect the desired differences in cross link density between the luminal and adventitial surfaces of the graft 32a.
  • the effected cross link density of a region or surface of the graft may be measured in terms of denaturation temperature T d .
  • the following table shows the relative differences in cross link density, as represented by differences in T d , of the luminal and adventitial surfaces of the graft 32d, as a function of exposure time:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Prostheses (AREA)

Abstract

Greffes de tissus prothétiques constituées de matériaux collagènes se trouvant chimiquement réticulés, une première région de la greffe (32) étant réticulée pour donner une première densité de réticulation, et une seconde région de la greffe (32) étant réticulée pour donner une seconde densité de réticulation. Les variations par région souhaitées dans la densité de réticulation de la greffe collagène (32) peuvent s'obtenir en exposant des portions ou régions spécifiques de la greffe (32) à différentes compositions et/ou concentrations de fixation et/ou à différentes conditions de réaction de fixation (par ex., pH, température, pression, temps d'exposition).
PCT/US1994/001012 1993-02-01 1994-01-28 Greffes biologiques ayant des differences par region sur le plan de la densite de reticulation et methodes de fabrication WO1994017841A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1160993A 1993-02-01 1993-02-01
US08/011,609 1993-02-01

Publications (1)

Publication Number Publication Date
WO1994017841A1 true WO1994017841A1 (fr) 1994-08-18

Family

ID=21751186

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/001012 WO1994017841A1 (fr) 1993-02-01 1994-01-28 Greffes biologiques ayant des differences par region sur le plan de la densite de reticulation et methodes de fabrication

Country Status (1)

Country Link
WO (1) WO1994017841A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032615A1 (fr) * 1996-03-04 1997-09-12 Baxter International Inc. Composes epoxy non polymeres destines a la reticulation de tissus biologiques et greffons pour bioprotheses ainsi obtenus
US5674298A (en) * 1994-10-21 1997-10-07 The Board Of Regents Of The University Of Michigan Calcification-resistant bioprosthetic tissue and methods of making same
WO1999027979A1 (fr) * 1997-12-02 1999-06-10 Baxter International Inc. Procede empechant la calcification des materiaux de bioprothese fixes par l'aldehyde
US6106555A (en) * 1998-12-15 2000-08-22 Av Healing Llc Method for tissue fixation
EP1343543A1 (fr) * 2000-12-20 2003-09-17 KETHARANATHAN, Vettivetpillai Methode de creation de materiau biologique et biosynthetique destine a l'implantation
GB2451785A (en) * 2004-03-29 2009-02-11 Cook Biotech Inc Medical graft having regions of different matrix structure
CN103796689A (zh) * 2011-07-28 2014-05-14 哈博医疗科技有限公司 交联的人或动物组织产品及其制造方法和使用方法
US9414843B2 (en) 2003-11-28 2016-08-16 Cook Medical Technologies Llc Vascular occlusion methods, systems and devices
US12102731B2 (en) 2020-05-01 2024-10-01 Harbor Medtech, Inc. Port-accessible multidirectional reinforced minimally invasive collagen device for soft tissue repair

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306256A2 (fr) * 1987-08-31 1989-03-08 Koken Co. Ltd. Valve bioprosthétique
EP0311305A1 (fr) * 1987-10-02 1989-04-12 Koken Company Limited Vaisseau sanguin artificiel
WO1992014419A1 (fr) * 1991-02-14 1992-09-03 Baxter International Inc. Materiaux biologiques flexibles pour greffes et leurs procedes de fabrication
EP0509833A1 (fr) * 1991-04-19 1992-10-21 Koken Co. Ltd. Composition pour l'injection intracorporelle pour l'implantation d'atelocollagène réticulé à haute concentration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306256A2 (fr) * 1987-08-31 1989-03-08 Koken Co. Ltd. Valve bioprosthétique
EP0311305A1 (fr) * 1987-10-02 1989-04-12 Koken Company Limited Vaisseau sanguin artificiel
WO1992014419A1 (fr) * 1991-02-14 1992-09-03 Baxter International Inc. Materiaux biologiques flexibles pour greffes et leurs procedes de fabrication
EP0509833A1 (fr) * 1991-04-19 1992-10-21 Koken Co. Ltd. Composition pour l'injection intracorporelle pour l'implantation d'atelocollagène réticulé à haute concentration

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUKIO ICHIKAWA: "A NEW RV-PA CONDUIT WITH A NATURAL VALVE MADE OF BOVINE JUGULAR VEIN.", ASAIO TRANSACTIONS, vol. 38, no. 3, September 1992 (1992-09-01), TORONTO, CA, pages 266 - 270, XP000321550 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674298A (en) * 1994-10-21 1997-10-07 The Board Of Regents Of The University Of Michigan Calcification-resistant bioprosthetic tissue and methods of making same
WO1997032615A1 (fr) * 1996-03-04 1997-09-12 Baxter International Inc. Composes epoxy non polymeres destines a la reticulation de tissus biologiques et greffons pour bioprotheses ainsi obtenus
WO1999027979A1 (fr) * 1997-12-02 1999-06-10 Baxter International Inc. Procede empechant la calcification des materiaux de bioprothese fixes par l'aldehyde
US6008292A (en) * 1997-12-02 1999-12-28 Baxter International Inc. Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials
US6106555A (en) * 1998-12-15 2000-08-22 Av Healing Llc Method for tissue fixation
US6231614B1 (en) 1998-12-15 2001-05-15 Av Healing Llc Method for tissue fixation
EP1343543A4 (fr) * 2000-12-20 2009-06-17 Vettivetpillai Ketharanathan Methode de creation de materiau biologique et biosynthetique destine a l'implantation
EP1343543A1 (fr) * 2000-12-20 2003-09-17 KETHARANATHAN, Vettivetpillai Methode de creation de materiau biologique et biosynthetique destine a l'implantation
US9414843B2 (en) 2003-11-28 2016-08-16 Cook Medical Technologies Llc Vascular occlusion methods, systems and devices
GB2451785B (en) * 2004-03-29 2009-03-25 Cook Biotech Inc Medical graft products with differing regions
US7959554B2 (en) 2004-03-29 2011-06-14 Cook Biotech Incorporated Medical graft products with differing regions and methods and systems for producing the same
GB2451785A (en) * 2004-03-29 2009-02-11 Cook Biotech Inc Medical graft having regions of different matrix structure
CN103796689A (zh) * 2011-07-28 2014-05-14 哈博医疗科技有限公司 交联的人或动物组织产品及其制造方法和使用方法
US8901078B2 (en) 2011-07-28 2014-12-02 Harbor Medtech, Inc. Crosslinked human or animal tissue products and their methods of manufacture and use
US9220808B2 (en) 2011-07-28 2015-12-29 Harbor Medtech, Inc. Crosslinked human or animal tissue products and their methods of manufacture and use
US9399084B2 (en) 2011-07-28 2016-07-26 Harbor Medtech, Inc. Crosslinked human or animal tissue products and their methods of manufacture and use
US9592320B2 (en) 2011-07-28 2017-03-14 Harbor Medtech, Inc. Crosslinked human or animal tissue products and their methods of manufacture and use
US10611822B2 (en) 2011-07-28 2020-04-07 Harbor Medtech, Inc. Crosslinked human or animal tissue products and their methods of manufacture and use
US12065480B2 (en) 2011-07-28 2024-08-20 Harbor Medtech, Inc. Crosslinked human or animal tissue products and their methods of manufacture and use
US12102731B2 (en) 2020-05-01 2024-10-01 Harbor Medtech, Inc. Port-accessible multidirectional reinforced minimally invasive collagen device for soft tissue repair

Similar Documents

Publication Publication Date Title
US4755593A (en) Novel biomaterial of cross-linked peritoneal tissue
EP1843659B1 (fr) Procede pour traiter un tissu biologique
EP0888142B1 (fr) Composes epoxy non polymeres destines a la reticulation de tissus biologiques et greffons pour bioprotheses ainsi obtenus
EP0571527B1 (fr) Procede de fabrication des materiaux biologiques flexibles pour greffes
JP3797673B2 (ja) 石灰化を軽減するための移植可能な生物学的組織の処理方法およびこのような方法で処理された生体補綴物
CA2273077C (fr) Greffes tubulaires formees a partir de sous-muqueuse purifiee
US6008292A (en) Method for inhibiting calcification of aldehyde-fixed bioprosthetic materials
RU2432968C2 (ru) Искусcтвенный биологический имплантат для направляющей оболочки нерва и способ его изготовления
AU734370B2 (en) Methods for actively binding heparin to biological and non- biological bioprosthetic material
JPH04505866A (ja) 生物学的弁補綴
US20110224779A1 (en) Thin collagen tissue for medical device applications
WO1994017841A1 (fr) Greffes biologiques ayant des differences par region sur le plan de la densite de reticulation et methodes de fabrication
Noishiki et al. Development and evaluation of a pliable biological valved conduit. Part I: preparation, biochemical properties, and histological findings
Ichikawa et al. A new antithrombogenic RV-PA valved conduit
US6926743B1 (en) Biological stent-graft
RU2809478C2 (ru) Способ предотвращения разложения и дегенерации ткани, используемой в биопротезах
WO2011115612A1 (fr) Tissu collagène mince pour des applications de dispositifs médicaux
Xeongraft Wright, CB, ed. Vascular Grafting, John Wright Pub., Littleton, Mass, Section II Large Vessel Grafts
JP2005501042A (ja) 酸化された生体補綴物質
July Novel biomaterial of cross-linked peritoneal tissue
GB2183475A (en) Tissue immunodespeciating and conserving product
AU2004216679A1 (en) Tubular submucosal graft constructs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载